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Abstract 
The storage condition, composition and application of 
platelet-rich plasma for cartilage regeneration 
Joong Il Kim 
Medicine (Orthopedic Surgery) 
The Graduate School 
Seoul National University 
 
Purpose: The purpose of this study was to investigate the practical use of platelet‐
rich plasma (PRP) for cartilage regeneration. For this purpose, the author evaluated 
1) the concentrations of growth factors in PRP, depending on the storage 
conditions; 2) the effects of leukocyte concentrations in PRP on the proliferation 
and chondrogenesis of synovial membrane-derived mesenchymal stem cells 
(SDSCs) and chondrocytes; and 3) in vivo effectiveness of PRP with a hyaluronic 
acid (HA) hydrogel for cartilage regeneration. 
   
Materials and Methods: To evaluate growth factor concentration in PRP based on 
storage conditions, PRP samples were stored at 24℃ (room temperature group), 4℃ 
(refrigerator group), and −70℃ (deep‐freezer group). In each temperature, four 
aliquots were prepared based on the time of analysis (immediately, 1, 3, 7 days 
after preparation). After storage, concentrations of platelet‐derived growth factor‐
AA (PDGF‐AA), transforming growth factor‐β (TGF‐β), vascular endothelial 
growth factor (VEGF), insulin‐like growth factor‐1 (IGF‐1), and fibroblast growth 
factor‐basic (FGF‐B) were assessed with/without activation using Quantikine 
colorimetric sandwich immunoassay kits. PRP was activated with 10% Triton‐X 
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for PDGF‐AA, VEGF, FGF‐B, IGF‐1 measurement and sonication for TGF‐β1 
measurement. 
To evaluate the effect of leukocyte concentrations in PRP on the proliferation and 
chondrogenesis of SDSCs and chondrocytes, we prepared two PRP formulations: 
(1) leukocyte-poor PRP (P-PRP) and (2) leukocyte-rich PRP (L-PRP). SDSCs and 
chondrocytes were obtained by enzymatic digestion of synovial tissues and the 
cartilage from a knee joint undergoing total knee arthroplasty. The primary cells 
were expanded in Dulbecco’s modified Eagle’s medium supplemented with fetal 
bovine serum (FBS), L-PRP, or P-PRP. Cell proliferation was measured using the 
MTT assay. SDSCs and chondrocytes were cultured with chondrogenic medium 
(CM) only, CM with L-PRP, or CM with P-PRP using a high-density pellet culture 
system for 3 weeks. The expression of chondrogenesis-related genes (type II 
collagen, type X collagen, aggrecan, and SOX-9) were analyzed by RT-qPCR. 
Pellets were stained with safranin-O for proteoglycan detection. The expression of 
type II collagen was detected by immunohistochemical staining. 
To evaluate the effect of PRP in combination with the HA hydrogel on in vivo 
cartilage regeneration, eighteen rabbit osteochondral defect models (round shape 
defect in the femoral trochlear groove with 4 mm in radius and 3 mm in depth) 
were made and divided into 3 groups: control group, in which the defect was left 
untreated; HA group, in which the defect was filled with the HA hydrogel; and 
HA-PRP group, in which the defect was filled with HA hydrogel and PRP. After 
12 weeks, tissue specimens were assessed by macroscopic examination, 
histological evaluation, and by measuring the glycosaminoglycan (GAG) content. 
 
Results: Regarding growth factor concentration in PRP based on storage 
conditions, PDGF‐AA concentration was highest on day 7 in the room temperature 
group without activation. With activation, the concentration of PDGF‐AA was 
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constant over the observation period at all temperatures. Without activation, the 
TGF‐β1 concentration remained negligible over the observation period at all 
temperatures. However, with activation, TGF‐β1 concentration was highest on day 
7 at all temperatures. Over the observation period, VEGF and IGF‐1 concentration 
were constant with and without activation at all temperatures. Without activation, 
FGF‐B concentration was highest on day 7 in the deep‐freezer group. With 
activation, FGF‐B concentration decreased after day 1 in the room temperature 
group.  
Regarding the effect of the leukocyte concentration in PRP on the proliferation and 
chondrogenesis of SDSCs and chondrocytes, L-PRP showed a stronger 
proliferative effect on both types of cells than P-PRP and FBS. Meanwhile, RT-
qPCR revealed higher cartilage-related gene expression in SDSCs and 
chondrocytes in the P-PRP group compared with that in the L-PRP and CM groups. 
However, SDSCs and chondrocytes in both PRP groups showed weaker safranin-O 
staining than those in the CM group. In immunohistochemical analysis, positive 
staining of SDSCs were not observed in either of the PRP groups and staining of 
chondrocytes in both PRP groups were weaker than those in the CM group. 
Regarding the effect of PRP combined with the HA hydrogel on in vivo cartilage 
regeneration, the macroscopic ICRS scores were not different among the three 
groups. The HA and HA-PRP groups showed significantly higher microscopic 
O’Driscoll scores and a significantly higher GAG content than the control group, 
although the values were not different between the HA and HA-PRP groups. 
 
Conclusion: The growth factor concentrations significantly differed in PRP, 
depending on the storage temperature, duration of storage, and activation. 
Regardless of the leukocyte concentration, PRP showed a negative effect on 
chondrogenesis of SDSCs and chondrocytes. In addition, a combined use of the 
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HA hydrogel and PRP did not show better chondrogenic effects in vivo compared 
with those of the HA hydrogel alone. Considering the results of our study, a further 
study is necessary to clarify the ideal composition and application of PRP for 
cartilage regeneration. 
Keywords: platelet rich plasma, storage, leukocyte, synovial stem cell, 
chondrogenesis, hyaluronic acid 
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Introduction 
Platelet-rich plasma (PRP) is a derivative of whole blood obtained by the 
process of centrifugation. It contains a high concentration of platelets that 
release several growth factors, such as platelet-derived growth factor (PDGF), 
transforming growth factor-beta (TGF-β), vascular endothelial growth factor 
(VEGF), insulin-like growth factor-1 (IGF-1), and fibroblast growth factor-
basic (FGF-B) contained in the constituent alpha (α) granules upon activation 
(1-3). Recent studies have shown that these growth factors participate in tissue 
regeneration by fostering cellular growth, proliferation, and differentiation (3-
5), leading to an increase in the popularity of PRP and its widespread 
application in orthopedic field.  
However, the effectiveness of PRP in cartilage regeneration remains 
controversial due to inconsistent clinical outcomes. There are several reasons 
for this inconsistency, among which differences in the PRP storage, 
composition, and application are one of the most important aspects (6-9). 
Indeed, the method for effective use of PRP for cartilage regeneration has not 
been well established. Therefore, we investigated three important aspects for 
practical use of PRP, namely, its storage, composition, and application. 
In the first part of this study, we evaluated the effect of PRP storage 
conditions on growth factor concentration. While PRP can be used 
immediately after its preparation, in practice, it may be stored for several 
reasons. One such reason is for modifying growth factor release kinetics. PRP 
contains several growth factors, each of which plays a unique role by acting on 
specific tissue components to promote tissue regeneration (10-13). Depending 
on the purpose of the PRP usage, some of the growth factors in PRP may be 
beneficial or harmful after application. Additionally, timing and duration of 
action of growth factors are important considerations for optimal effect. 
- ２ - 
Several studies (14-17) have reported that differences in storage conditions of 
time and temperature of PRP can alter growth factor release. Therefore, by 
controlling storage conditions of time and temperature, it may be possible to 
maximize or minimize the amount of specific growth factors in PRP, 
depending on the intended clinical use. Further, storage of PRP may be needed 
for the purpose of repeated injections at specific time intervals. Several studies 
(18, 19) have shown that repeated PRP injections are associated with better 
clinical outcomes than a single injection. Therefore, the effect of storage 
conditions, including time and temperature, on PRP needs to be elucidated. 
Moreover, it is unclear whether activation of PRP, following a period of 
storage, prior to its use is beneficial. Activation of platelets releases growth 
factors in the 𝛼-granules and causes gelation of PRP, facilitating its application. 
Hence, some physicians prefer to activate PRP before its use. However, others 
prefer it without activation as ex vivo activation is associated with concerns of 
early washout of the released growth factors, whereas PRP activation by the 
native collagen of connective tissue in vivo results in slow release of growth 
factors (20-24). Thus, to clarify the effect of PRP, it is important to evaluate 
growth factor concentration with and without activation under different storage 
conditions. 
While earlier studies (14-16, 25-27) have examined growth factor 
concentration, data on the effect of various storage conditions on the 
concentration of various growth factors in PRP are limited. In addition, none 
of these studies compared the effect of storage and activation on growth factor 
concentrations in PRP.  
 Therefore, the purpose of the first topic was to evaluate growth factor 
concentration in PRP based on storage conditions, with or without activation.  
In the second part of this study, we evaluated the effect of leukocyte 
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concentrations in PRP on the proliferation and chondrogenesis of synovial 
membrane-derived mesenchymal stem cells (SDSCs) and chondrocytes. There 
are various methods of PRP preparation; however, research on the 
characteristics of PRP obtained by different methods is insufficient (26-28). In 
particular, differences in leukocyte concentrations in PRP may affect PRP 
properties (29-33), leading to different cartilage regeneration results. However, 
there is a paucity of the literature data regarding this aspect. 
Furthermore, there is a growing interest in the use of mesenchymal stem cells 
(MSCs) for the treatment of articular cartilage damage. As multipotent cells, 
MSCs have the abilities to self-renew and differentiate into articular cartilage 
(34, 35). MSCs can be obtained from several tissues, such as the bone marrow, 
synovial membrane, and adipose tissue. Among them, SDSCs have higher 
proliferation and chondrogenic differentiation potential compared to MSCs 
derived from other tissues (36, 37). Moreover, because the synovial membrane 
is located near the articular cartilage of the knee, SDSCs can be easily 
obtained through a minimal incision, without donor site morbidity. 
However, MSCs that are directly obtained from tissues are too small to be 
directly applied for cartilage repair. Therefore, before their clinical use, 
expansion of MSCs is necessary through in vitro culture. There are some 
reports (38-41) indicating that PRP enhances the proliferation and 
chondrogenesis of MSCs. However, most studies used stem cells obtained 
from the bone marrow or adipose tissue. Meanwhile, only one study (42) 
investigated the effect of PRP on SDSCs; however, a platelet concentrate was 
used in this study. To the best of our knowledge, there has been no study that 
evaluated the effect of the leukocyte concentration in PRP on the proliferation 
and chondrogenesis of SDSCs and chondrocytes. Therefore, the purpose of the 
second topic was to investigate the effect of leukocyte concentrations in PRP 
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on the proliferation and chondrogenesis of SDSCs and chondrocytes. 
In the last part of this study, we evaluated the effect of PRP, in combination 
with a hyaluronic acid (HA) hydrogel, on in vivo cartilage regeneration. The 
articular surface is composed of the hyaline cartilage, which is unable to heal 
spontaneously, owing to its avascular nature and the inability to support 
chondrocyte migration to an injured site (43, 44). Various surgical procedures 
have been used for cartilage repair, including microfracture (45), 
osteochondral autograft or allograft transplants (OATs) (46), and autologous 
chondrocyte implantation (ACI) (47). The microfracture method is used for 
relatively small cartilage lesions (< 2 cm2), whereas OATs or ACI is used for 
larger cartilage lesions (> 2 cm2). However, the microfracture technique has 
the disadvantage of regenerating a fibrous cartilage rather than the hyaline 
cartilage. Furthermore, OATs and ACI have the disadvantages of causing 
donor site morbidity and requiring two invasive surgeries, respectively (48, 
49). 
Recent studies (50-53) have shown superior results of scaffold-assisted 
cartilage regeneration techniques. Scaffolds may provide a suitable 
environment for bone marrow stem cell (BMSC) infiltration, proliferation, 
and differentiation, thus leading to better cartilage regeneration (54, 55). 
Among various currently used scaffolds, HA-based hydrogels are especially 
promising for cartilage regeneration because HA is a major natural 
macromolecular component of the extracellular matrix (ECM) of the articular 
cartilage and has excellent biocompatibility and mechanical properties (56-58). 
The benefits of scaffold application for cartilage regeneration may be further 
enhanced by the use of PRP, owing to the presence of various growth factors, 
which can stimulate the proliferation and chondrogenesis of BMSCs and 
chondrocytes (10-13). Therefore, it is important to ensure that adding PRP 
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would lead to superior cartilage healing compared with that supported by a 
hydrogel alone. Hence, the purpose of the last topic was to evaluate the effect 
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I-1. Materials and Methods 
 
Preparation of PRP 
From donated human fresh blood from six donors (Asian males, 34.2 ± 5.3; 
range: 30–43 years), 320 ml of peripheral venous blood was collected and 
mixed with the anticoagulant 10% acid‐citrate dextrose A (ACD‐A). To 
prepare PRP, 25ml of this blood was transferred to the PRP separation kit 
(Prosys PRP Kit, Prodizen, Korea) and centrifuged at 2,800 rpm for 3 min. 
The upper layer of plasma was separated and subjected to a second round of 
centrifugation at 3,300 rpm for 3 min following which, the lower 2ml of 
plasma was collected as PRP. 
 
Storage and Activation of PRP 
The PRP samples from each donor were stored at three different storage 
temperatures: 24℃ (room temperature group), 4℃ (refrigerator group), and 
−70℃ (deep‐freezer group). From the PRP stored at each temperature, four 
aliquots were prepared based on the time of analysis. While one aliquot was 
analyzed immediately after preparation, the remaining three were stored for 1, 
3, and 7 days. After the specified storage time, the aliquots in the deep‐freezer 
were thawed to room temperature prior to analysis. After storage, PRP 
activation was done with 10% Triton‐X followed by incubation for 1 h at 37℃ 
for PDGF‐AA, VEGF, FGF‐B, and IGF‐1 measurement and sonication 
(Digital Sonifier 450; Branson, Danbury, CT) for TGF‐β1 measurement. 
Sonication was performed with a total of 10 repetitions of the sonicating‐
cooling cycle (1 min for 1 cycle) for 10 min. 
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Evaluation of Platelet Count and Growth Factor Concentrations in PRP 
The platelet, white blood cell (WBC), and red blood cell (RBC) counts of 
PRP were performed before the analysis of serial platelet count and growth 
factor concentration, using a cell count machine (ADVIA 2120i; Siemens, 
Erlangen, Germany). After storage, the samples were assayed in duplicate, 
and the platelet count and concentrations of growth factors in each aliquot 
were assessed. The platelet count of each aliquot was determined using a cell 
counter machine. Concentrations of growth factors PDGF‐AA, TGF‐β1, 
VEGF, IGF‐1, and FGF‐B in each aliquot were measured with and without 
activation, using commercially available Quantikine colorimetric sandwich 
immunoassay kits (R&D Systems, Minneapolis, MN). 
 
Statistical Analysis 
Data are presented as mean and standard deviation (SD). The Friedman test 
was used to determine whether the platelet count and growth factor 
concentration changed significantly during the time of storage in each group. 
The concentrations of growth factors at the end of each specified storage time 
were analyzed using the Kruskal–Wallis test (nonparametric one‐way analysis 
of variance). Bonferroni post hoc analysis was used to compare the values of 





Cellular Concentration of PRP 
The mean platelet, WBC, and RBC counts of PRP were 1,588 ± 176.9 × 
103/μl, 13.5±3.3 × 103/μl, 1.5±1.0 × 106/μl, respectively. 
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Platelet Count 
In the deep‐freezer group, the platelet count was significantly decreased on 
day 1 from 1,588 ± 176.9 × 103/μl to 1,325 ± 278.2 × 103/μl (p < 0.05), but 
remained constant thereafter until day 7. The platelet counts in the room 
temperature and refrigerator groups stayed constant (Figure 1). 
 
Growth Factor Concentrations Under Various Storage Conditions and 
Activation 
PDGF‐AA 
Without activation, the release of PDGF-AA during storage was constant over 
the observation period in the refrigerator and deep‐freezer groups. However, 
in the room temperature group, the highest PDGF‐AA concentration was 
observed on day 7 (p < 0.05), which was significantly greater than that in the 
refrigerator 
(p < 0.05) and deep‐freezer (p < 0.05) groups. With activation, the release of 
PDGF‐AA was constant over the observation period at all three temperatures 
(Figure 2).  
 
TGF‐β1  
Without activation, the release of TGF‐β1 during storage were negligible over 
the observation period at all three temperatures. With activation, the 
concentration of TGF‐β1 increased at each time point and was highest on day 
7 at all three temperatures (p < 0.05 for all three temperatures) (Figure 3). 
 
VEGF and IGF‐1 
Without activation, the release patterns of VEGF (Figure 4) and IGF‐1 (Figure 
5) during storage were similar to the levels remaining constant over the 
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observation period at all three temperatures. With activation, the release of 




Without activation, the release of FGF‐B during storage significantly 
increased in the deep‐freezer group, with levels reached highest concentration 
on day 7 (p < 0.05), whereas FGF‐B levels were negligible in the room 
temperature and refrigerator groups. Therefore, FGF‐B concentration in the 
deep‐freezer was significantly higher on days 1, 3, and 7 than that in the room 
temperature (p < 0.05 on days 1, 3, and 7) and refrigerator (p < 0.05 on days 1, 
3, and 7) groups. With activation, the release of FGF‐B remained constant 
over the observation period in both the refrigerator and deep‐freezer groups, 
while significantly decreasing after day 1 in the room temperature group (p < 
0.05), such that on days 3 and 7, FGF‐B concentration was significantly lower 
in the room temperature group than that in the refrigerator (p < 0.05 on days 3 
and 7) and deep‐freezer groups (p < 0.05 on days 3 and 7) (Figure 6). 
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Figure 1. Changes in platelet count at different storage temperatures. The 
bars show the mean platelet count at each time point of the specified 
temperature (n = 6), vertical lines represent standard errors of the means, (*) 
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Figure 2. Growth factor release profile of platelet-derived growth factor 
(PDGF)-AA at different storage temperatures without (dotted bars) and with 
activation (solid bars). The bars show the mean values of growth factors at 
each time point of the specified temperature group (n = 6): dotted bars show 
PDGF-AA concentration without activation and solid bars show total amount 
of PDGF-AA release with activation. Vertical lines represent standard errors 
of the means, (*) represents statistically significant time-dependent changes in 
each group, (a) represents p < 0.05 compared with the refrigerator group, (b) 
represents p < 0.05 compared with the deep-freezer group at the same time 
points. NA; Not activated, A; Activated.  
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Figure 3. Growth factor concentration of transforming growth factor (TGF)-
β1 at different storage temperatures without (dotted bars) and with activation 
(solid bars). The bars show the mean values of growth factors at each time 
point of the specified temperature group (n = 6): dotted bars show TGF-β1 
concentration before activation and solid bars show total amount of TGF-β1 
release with activation. Vertical lines represent standard errors of the means, 
(*) represents statistically significant time-dependent changes in each group. 
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Figure 4. Growth factor concentration of vascular endothelial growth factor 
(VEGF) at different storage temperatures without (dotted bars) and with 
activation (solid bars). The bars show the mean values of growth factors at 
each time point of the specified temperature group (n=6): dotted bars show 
VEGF concentration without activation and solid bars show total amount of 
VEGF release with activation. Vertical lines represent standard errors of the 
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Figure 5. Growth factor concentration of insulin-like growth factor-1 (IGF-1) 
at different storage temperatures without (dotted bars) and with activation 
(solid bars). The bars show the mean values of growth factors at each time 
point of the specified temperature group (n=6): dotted bars show IGF-1 
concentration without activation and solid bars show total amount of IGF-1 
release with activation. Vertical lines represent standard errors of the means. 
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Figure 6. Growth factor concentration of fibroblast growth factor-basic (FGF-
B) at different storage temperatures without (dotted bars) and with activation 
(solid bars). The bars show the mean values of growth factors at each time 
point of the specified temperature group (n = 6): dotted bars show FGF-B 
concentration without activation and solid bars show total amount of FGF-B 
release with activation. Vertical lines represent standard errors of the means, 
(*) represents statistically significant time-dependent changes in each group. 
(a) represents p < 0.05 compared with the room temperature group and (b) 
represents p < 0.05 compared with the refrigerator group at the same time 
points. (c) represents p < 0.05 compared with the refrigerator group and (d) 
represents p < 0.05 compared with the deep-freezer group at the same time 
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I-3. Discussion 
This study found that growth factor concentration in PRP differed 
significantly based on storage temperature, duration of storage, and method of 
ex vivo activation used in this study. Without activation, while the 
concentration of TGF-β1 was negligible, that of VEGF and IGF-1 remained 
constant over the seven-day observation period. Also, PDGF-AA in the room 
temperature group and FGF-B in the deep-freezer group reached their highest 
concentrations on day 7. With activation, most growth factors showed a 
constant release pattern over 7 days, with TGF-β1 reaching its highest 
concentration on day 7. An exception to this was FGF-B, which showed poor 
release pattern in the room temperature group. Therefore, depending on the 
intended clinical use, it is necessary to consider the role of appropriate storage 
conditions and activation to maximize the effect of PRP. 
Care should be taken when interpreting the growth factor concentration of 
PRP stored in the deep-freezer. Unlike PRP stored at room temperature or in 
the refrigerator, thawing is necessary to analyze growth factors in PRP stored 
in the deep-freezer. Although this process does not involve a repeated 
freeze/thaw cycle, it can still result in unintentional PRP activation. In our 
study, platelet count and FGF-B concentration were greatly influenced by the 
thawing process. Platelet count decreased significantly on day 1 in PRP stored 
in the deep-freezer, possibly owing to cell lysis during thawing. Moreover, 
before iatrogenic activation, the concentration of FGF-B significantly 
increased on day 1 in PRP stored in the deep-freezer, which may be attributed 
to the activation effect of thawing. With regard to the concentrations of other 
growth factors, there was no significant increase between day 0 and day 1 
before iatrogenic activation, suggesting that the activation effect of thawing 
was nonsignificant as compared to that seen in FGF-B. 
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Among the various growth factors contained in the α-granules, PDGF-AA, 
TGF-β1, VEGF, IGF-1, and FGF-B play key roles in tissue regeneration (59, 
60). Given their important roles in tissue regeneration, we selected the 
aforementioned growth factors to be evaluated in our study. The growth factor 
concentration was assessed at four time points: 0, 1, 3, and 7 days after 
storage. Considering that the life span of platelets is 8 to 9 days, we assumed 
that the day 1 assay would detect early depletion of growth factors, day 3 
assay would detect intermediate depletion, and day 7 assay would confirm 
sustained release of growth factors.  
While PRP can be used immediately after its preparation, in practice, it may 
be needed to be stored until the time of its use. It is known that platelets 
remain active for 5 to 7 days at room temperature or up to 10 days at 
temperatures of 0°C to 6℃ (61, 62). However, the number of studies dealing 
with growth factor release kinetics in PRP stored under different conditions is 
limited. Bausset et al. (63) reported that the concentrations of PDGF-AB and 
VEGF were well-sustained at room temperature up to 6 hours. Similarly, 
Wilson et al. (17) reported that TGF-β1 could be used without loss of activity 
up to 4 hours at room temperature. There are studies that observed changes in 
growth factor concentration over a few days. Moore et al. (15) measured the 
levels of PDGF-BB over 8 days and showed that PRP intended for tissue 
regeneration could be stored at room temperature for at least 5 days, without 
loss of efficacy. Similarly, Wen et al. (16) reported that the concentrations of 
VEGF, epidermal growth factor (EGF), FGF-B, IGF-1, and PDGF-AA were 
not only sustained but also showed an increase after 7 days at storage 
temperature of 22°C. However, Hosnuter et al. (14) found that the levels of 
EGF, VEGF, PDGF, IGF-1, and TGF-β1 were significantly decreased after 7 
days in PRP stored at -20℃. In our study, with activation, the concentration 
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of all growth factors (except for FGF-B) were similar at each time point tested 
during 7 days of storage, regardless of storage temperature, with TGF-β1 
reaching its highest concentration on day 7.  
Activation of PRP causes degranulation of α-granules and triggers the 
clotting system through cleavage of fibrinogen resulting in gelation of PRP, 
which facilitates its application (21). For this purpose, many physicians prefer 
to activate PRP using various activation methods, such as use of calcium 
chloride, collagen, thrombin, calcium chloride/thrombin mixture, or 
freeze/thaw cycle (25, 27). However, these methods are associated with 
concerns of early washout of the released growth factors, prompting other 
physicians to use non-activated PRP, thereby relying on native collagen at the 
desired site to promote activation, resulting in slow growth factor release (20, 
22-24). To clarify the effect of activation on growth factor release, we 
evaluated the growth factor concentration with and without activation in the 
present study. In accordance with the findings of Oh et al. (26), our study 
showed that some degree of growth factor existed before the intentional 
exogenous activation of PRP. This is possibly owing to pre-existed growth 
factor in normal plasma, inevitable activation during centrifugation in the 
preparation phase, or due to platelet aging and consequent loss of membrane 
integrity during the storage phase.  
There are numerous PRP activation methods, each with a varying effect on 
the timing and amount of growth factors released. When calcium chloride or 
collagen is used for activation, a low level of endogenous thrombin is formed, 
enabling sustained growth factor release for a long period of time (25, 64). 
However, when thrombin is used as an activator, it rapidly aggregates 
platelets and results in immediate release of growth factors that lasts only for 
a brief period (65, 66). While it is known that the total amount of growth 
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factors released is affected by the activation method used, there is no 
consensus as to which method results in the release of the highest amount of 
specific growth factors. Kim et al. (67) compared four activation methods and 
reported that calcium chloride alone was the best activator for FGF-B, Triton-
X and calcium chloride/thrombin mixture for PDGF, and thrombin/calcium 
chloride/collagen mixture for VEGF release. Regarding TGF-β1, there are 
several reports that the amount of TGF-β1 released by sonication is higher 
than that with other activation methods (68, 69). Liao et al. (68) reported in 
their systematic review that the concentration of TGF-β1 was 10 to 120 
ng/mL when activation was done using thrombin or thrombin/calcium 
chloride mixture, while the levels were nearly three times as much (300 
ng/mL) with the use of sonication. In this study, we aimed to measure the 
highest concentration of the growth factor present in PRP following activation, 
at each of the time points of interest. To this end, we performed a pilot study 
to determine the method of activation associated with the greatest amount of 
growth factors released. In this pilot study, three aliquots of 300 μL of human 
PRP from three donors were activated using calcium chloride/thrombin 
mixture (14 mg/mL of calcium chloride with 135 unit/mL of thrombin 
powder), 10% Triton-X, and sonication, respectively. The release of PDGF-
AA and TGF-β1 was measured and we found that activation using Triton-X 
yielded the highest concentration of PDGF-AA, while sonication was 
associated with highest levels of TGF-β1. Therefore, we used these activation 
methods in the present study. However, the reason for the difference in best 
activator for specific growth factor is not well known. Considering that all 
growth factors are contained in the same α-granules in the platelet, it is 
certainly difficult to explain. However, the mechanism of growth factor 
release from α-granules is not a simple degranulation process. Before platelet 
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activation, growth factors in α-granules remain in an inactive form. However, 
after activation, α-granules fuse with the platelet membrane, and the inactive 
growth factors are converted to their bioactive forms via addition of histones 
and carbohydrate side chain and are finally released from the platelet (70, 71). 
We assume that the method of activation differently influenced the activation 
process of each growth factor and led to the difference in the total amount of 
growth factors measured. Nonetheless, further studies are warranted to 
investigate the exact mechanism for the observed difference in the best 
activator for specific growth factor.  
This study has several limitations, which must be considered while 
interpreting the findings. First, the activation methods used in this study 
(determined from the pilot study) were chosen based on their ability to release 
the highest amount of PDGF-AA and TGF- β1 at the initial time point. 
Therefore, the activation protocol used here may not be the best protocol for 
later time points after storage and for other growth factors (except PDGF-AA 
and TGF- β1). Secondly, this study was conducted in vitro. However, growth 
factor concentrations are subjected to influences from various cellular 
interactions in vivo. Therefore, a further well-designed in vivo study is needed 
to verify the findings of our study. Third, properties of PRP may be 
influenced by inter-individual variability. The donors in our study were young 
male individuals from the Asian population, and growth factor release 
patterns might be different for older individuals, female individuals, and 
individuals of other ethnicities. Finally, the PRP preparation method used in 
this study yielded PRP containing some amount of white blood cells, which 
could have influenced growth factor concentration. 
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II-1. Materials and Methods 
 
Preparation of P-PRP, L-PRP 
Using fresh blood from six Asian male donors (35.1 ± 4.7 years; range: 32–43 
years), we prepared two PRP formulations: (1) PRP with a very few 
leukocytes (Leukocyte poor PRP, P-PRP) and (2) PRP with high 
concentrations of leukocytes (Leukocyte rich PRP, L-PRP). To prepare these 
PRP formulations, 25 mL of whole blood was transferred to a Prosys PRP 
separation kit (Prodizen) and centrifuged at 2,800 rpm for 3 min. The upper 
layer of the plasma was separated with a buffy coat (L-PRP) or without a 
buffy coat (P-PRP) and subjected to a second round of centrifugation at 3,300 
rpm for 3 min. Finally, the lower 2 mL of the plasma was collected as PRP. 
Platelet and WBC counts were estimated in both PRP formulations using a 
cell counting machine (ADVIA 2120i). To activate the plasma, we added a 
thrombin powder (135 U/mL) and calcium chloride (14 mg/mL). 
 
Harvest of Synovial and Cartilage Tissues 
Synovial tissues were harvested from the suprapatellar pouch, and cartilage 
tissues were harvested from the lateral femoral and tibial condyles of six 
female patients undergoing total knee arthroplasty. The average age of the 
patients was 72.2 years (range: 67–75 years). All patients had severe medial 
compartmental osteoarthritis (OA), and therefore, the cartilages were 
relatively intact in the lateral femoral and tibial condyles. The exclusion 
criteria were inflammatory arthritis such as rheumatoid arthritis, prior 
infective arthritis, and a major knee trauma. 
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Isolation and In Vitro Expansion of SDSCs and Chondrocytes 
After removal of adipose and periosteal tissues, synovial tissues were finely 
minced in phosphate-buffered saline and then digested with 0.02% 
collagenase (Sigma–Aldrich, St. Louis, MO, USA) overnight at 37℃. The 
cartilage was digested with 0.2% pronase (Sigma–Aldrich) for 1 h and with 
0.2% collagenase (Sigma–Aldrich) overnight at 37℃. The resultant cells were 
filtered through a 70-μm sieve to remove undigested tissue and then 
centrifuged at 1,500 rpm for 5 min. Afterward, the cells were cultured in low-
glucose Dulbecco’s modified Eagle’s medium (LG-DMEM; Gibco, Paisley, 
UK) containing 10% fetal bovine serum (FBS) and a 1% antibiotic–
antimycotic solution (100 U/mL penicillin, 100 mg/mL streptomycin, and 
0.25 mg/mL amphotericin B; Gibco) in an incubator at 37℃ with 5% CO2. 
The culture medium was changed every 3 days. When the passage 0 (P0) cell 
population reached 80–90% confluence (after 10–14 days), the cells were 
separated using trypsin–EDTA (0.25% trypsin, 0.53 mM EDTA; Life 
Technologies, Rockville, MD, USA) and plated at a density of 2 × 105 
cells/150-mL dish (P1). After repeated passage, as described above, cells (P2) 
were used for pellet culture. 
 
SDSC and Chondrocyte Proliferation Assay 
Primary (P0) SDSCs and chondrocytes were seeded onto 96-well plates (Nunc, 
Roskilde, Denmark) at a density of 5 × 103 per well. Cells were grown in LG-
DMEM supplemented with 10% FBS, P-PRP, or L-PRP for 48 h at 37°C with 
5% CO2. The PRP concentrations were selected based on our previous study 
(42). For proliferation analysis, cell viability was measured after 48 h using 
the MTT assay. Briefly, 20 mL of the CellTiter 96®  AQueous One Solution 
reagent (Promega, Fitchburg, WI, USA), containing the MTS tetrazolium 
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compound and an electron coupling reagent (phenazine ethosulfate), was 
added to each well containing 100 µL of LG-DMEM and incubated for 2 h. 
Absorbance was measured at 490 nm using a microplate reader (VersaMax; 
Molecular Devices, Sunnyvale, CA, USA), with the SoftMax®  ver. 5.2 
program (Molecular Devices). The assay was repeated three times. 
 
In Vitro Chondrogenesis Using Pellet Culture 
Cell suspensions (P2) containing 5 × 105 chondrocytes or SDSCs were 
centrifuged at 1,500 rpm for 5 min to obtain cell pellets. The cell pellets were 
cultured in chondrogenic medium (CM) or CM supplemented with 10% L-
PRP or P-PRP. The name and the composition of the groups are shown in 
Table 1. The chemically defined CM was composed of LG-DMEM 
containing 0.1 mmol/L ascorbic acid 2-phosphate, 100 nmol dexamethasone, 
40 µg/mL proline, 100 U/mL penicillin, 100 µg/mL streptomycin, ITS Premix 
(BD Biosciences, Bedford, MA, USA), and 10 ng/mL TGF-β1. The cell 
pellets were cultured at 37℃ with 5% CO2, and the medium was changed 
every other day. The cell pellets were harvested for evaluation of 
chondrogenesis after 21 days. 
 
Reverse Transcription–Quantitative Polymerase Chain Reaction (RT-qPCR) 
After 21 days in culture, total RNA was extracted from cell pellets using the 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and complementary DNA 
was synthesized using the RevertAid™ first-strand cDNA synthesis kit 
(Thermo Scientific, Waltham, MA, USA). Expression of chondrogenic 
marker genes, including those encoding aggrecan, Sry-type high-mobility-
group box transcription factor-9 (Sox-9), type II collagen, and type X collagen, 
was assessed using RT-qPCR. The Primer Express software version 1.5 
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(Applied Biosystems, Abingdon, UK) was used for RT-qPCR analysis, and 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene for normalization of the results. Gene expression levels 
were analyzed using an ABI Prism 7000 sequence detection system with a 
relative standard curve method. 
 
Histology and Immunohistochemistry 
For histological evaluation of glycosaminoglycan (GAG) synthesis, cell 
pellets from each group were stained with safranin-O/fast green on day 21, as 
described in our previous study (72). The expression of type II collagen was 
analyzed by immunohistochemical staining on day 21, as described in our 
previous study (72). Positive results were defined as a dense brown color 
surrounded by a blue color. 
 
Statistical Analysis 
The Kruskal–Wallis test, followed by multiple significance analyses, 
involving the Mann–Whitney test, was used to compare the scores and gene 
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Table 1. Name and medium composition of the groups 
Group Composition 
CM group Chondrogenic medium only 
P-PRP group Chondrogenic medium + 10% P-PRP 
L-PRP group Chondrogenic medium + 10% L-PRP 
CM, chondrogenic medium; P-PRP; Leukocyte poor PRP; L-PRP, 
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II-2. Results 
 
Cellular Concentration of L-PRP, P-PRP 
The mean platelet counts were not different between L-PRP and P-PRP (1,621 
± 152.7 × 103/μL vs. 1,425 ± 134.6 × 103/μL, respectively). However, the 
WBC counts were significantly higher in L-PRP than in P-PRP (10.5 ± 2.6 × 
103/μL vs. 0.1 ± 0.2 × 103/μL, respectively; p < 0.05). 
 
Proliferation of SDSCs and Chondrocytes in Different Media 
Proliferation of SDSCs and chondrocytes was significantly higher in the L-
PRP group than in the FBS and P-PRP groups (p < 0.05 for all comparison). 
However, it was not different between the FBS and P-PRP groups (Figure 7). 
 
Gene Expression of Chondrogenic Markers 
The gene expression of chondrogenic markers were measured by RT-qPCR 
on day 21. In SDSCs, the gene expression levels of aggrecan, type II collagen, 
and type X collagen were significantly higher in the P-PRP group than in the 
CM and L-PRP groups (p < 0.05 for all comparison). The gene expression 
levels of Sox-9 were significantly higher in the CM and P-PRP groups than in 
the L-PRP group (p < 0.05 for all comparison) but were not different between 
the CM and P-PRP groups (Figure 8). In chondrocytes, the gene expression 
levels of aggrecan, type II collagen, and Sox-9 were significantly higher in the 
P-PRP group than in the CM and L-PRP groups (p < 0.05 for all comparison). 
The gene expression levels of type X collagen were significantly higher in the 
P-PRP and L-PRP groups than in the CM group (p < 0.05 for all comparison) 
but were not different between the P-PRP and L-PRP groups (Figure 9). 
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Histological Analysis 
The presence of proteoglycans was assessed using safranin-O/fast green 
staining on day 21. In SDSCs and chondrocytes, the densest positive staining 
was observed in the CM group. Although better staining was observed in the 
P-PRP group than in the L-PRP group, both groups showed weaker staining 
than did the CM group for both SDSCs and chondrocytes (Figure 10).  
 
Immunohistochemical Analysis 
Immunohistochemistry was used to detect type II collagen on day 21. In 
SDSCs, the densest positive staining was observed in the CM group, while no 
positive staining was observed in either P-PRP or L-PRP group. In 
chondrocytes, although better staining was observed in the P-PRP group than 
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Figure 7. Proliferation of SDSCs (A) and chondrocytes (B) in different 
medium after 48 hours. SDSCs and chondrocytes proliferation were 
significantly higher in L-PRP group compared to P-PRP and FBS groups. 
Results are presented as mean ± SD (n = 6). * and ^ indicate significant 
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Figure 8. RT-PCR analysis for chondrogenic marker gene expression in 
SDSCs after 21 days of culture period. Results are presented as mean ± SD (n 
= 6). * and ^ indicate significant difference compared to CM group and L-
PRP group, respectively (p < 0.05). CM: chondrogenic medium; P-PRP: 
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Figure 9. RT-PCR analysis for chondrogenic marker gene expression in 
chondrocytes after 21 days of culture period. Results are presented as mean ± 
SD (n = 6). * and ^ indicate significant difference compared to CM group and 
L-PRP group, respectively (p < 0.05). CM: chondrogenic medium; P-PRP: 
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Figure 10. Histological evaluation of proteoglycan in the pellets with 
Safranin O-fast green staining. Pellets formed by SDSCs and chondrocytes 
were differentiated with various mediums and evaluated at day 21. 
Magnification, x100. CM: chondrogenic medium; P-PRP: Leukocyte poor 





- ３４ - 
 
 
Figure 11. Immunohistochemistry evaluation of type II collagen in the pellets. 
Pellets formed by SDSCs and chondrocytes were differentiated with various 
mediums and evaluated at day 21. Magnification, x100. CM: chondrogenic 
medium; P-PRP: Leukocyte poor PRP; L-PRP: Leukocyte rich PRP 
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II-3. Discussion 
The most important findings in this study were that (1) L-PRP showed better 
proliferative effects on SDSCs and chondrocytes than P-PRP and (2) both L-
PRP and P-PRP showed negative effects on chondrogenesis of SDSCs and 
chondrocytes. 
Recently, DeLong et al. (73) have proposed the PAW (Platelets, Activation, 
and White cells) classification system based on three components: (1) the 
absolute number of platelets; (2) the method of activation; and (3) the 
leukocyte concentration in PRP. Among the three components, the most 
important distinguishing characteristic of PRP is the leukocyte concentration. 
L-PRP has several advantages and disadvantages compared with P-PRP. 
Regarding advantages, leukocytes contain cytokines involved in an immune 
response to infection (33). Also, leukocytes can increase the total amount of 
growth factor released in the PRP (29). Regarding disadvantages, leukocytes 
can increase the levels of proinflammatory cytokines such as IL-1 and TNF‑α, 
which may adversely affect cartilage regeneration (31, 32). Moreover, 
leukocytes also increase the levels of matrix metalloproteinases (MMPs), 
which accelerate the degradation of ECM (30). 
Several studies have reported the effects of PRP on cartilage regeneration 
(39, 40, 42, 74-78); however, most of these studies have not clearly indicated 
the leukocyte concentration in PRP. Only two studies directly compared L-
PRP and P-PRP in terms of their effects on cartilage regeneration. Cavello et 
al. (38) compared the effects of L-PRP and P-PRP on human chondrocytes in 
vitro and showed that both formulations stimulated chondrocyte proliferation. 
However, regarding chondrogenesis, P-PRP stimulated type II collagen and 
aggrecan gene expression, whereas L-PRP induced higher expression of the 
HA synthase-2 gene than P-PRP did. Therefore, the authors concluded that 
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optimization of the leukocyte concentration might result in a more suitable 
PRP for the treatment of cartilage lesions. In addition, Xu et al. (41) 
performed an in vitro and in vivo study using rabbits and have reported that 
better proliferation and chondrogenic differentiation of rabbit BMSCs, as well 
as better cartilage regeneration in a rabbit osteochondral defect model, were 
observed in the presence of P-PRP than with L-PRP; therefore, the authors 
concluded that P-PRP might be more suitable for cartilage regeneration. 
However, no study compared P-PRP and L-PRP in terms of their effects on 
cartilage regeneration using human SDSCs.  
In our study, L-PRP showed better proliferative effects on SDSCs and 
chondrocytes than P-PRP did. However, although RT-qPCR revealed higher 
gene expression of chondrogenic markers in SDSCs and chondrocytes 
cultured with P-PRP than in those cultured with L-PRP, histological and 
immunohistochemical findings suggested that both types of PRP had negative 
effects on chondrogenesis of SDSCs and chondrocytes. Our findings are 
certainly difficult to explain, but opposite effects of PRP on the proliferation 
and chondrogenesis were also observed in other studies (74-76). Drengk et al. 
(74) reported that PRP showed a proliferative effect on sheep BMSCs, while 
downregulated type II collagen gene expression. The explanation was that the 
proliferation and differentiation could not occur at the same time, and 
therefore, increased proliferation led to a decrease in the differentiation 
potential of BMSCs. Additionally, Kaps et al. (76) reported that PRP 
stimulated chondrocyte proliferation but failed to stimulate chondrocytes to 
redifferentiate in three-dimensional cultures. Therefore, the authors concluded 
that PRP might be suitable for chondrocyte expansion but not for the 
maturation of a tissue-engineered cartilage. Similar findings were reported in 
a study by Gaissmaier et al. (75), who found that PRP enhanced the 
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chondrocyte proliferation in monolayer cultures but induced dedifferentiation 
of chondrocytes toward a fibroblast-like phenotype. 
Regarding better proliferative effects of L-PRP, several reports (29, 38) 
showed that leukocytes in PRP could further increase the levels of anabolic 
growth factors such as TGF-β, PDGF-AB, and VEGF. We assume that the 
abundance of growth factors in L-PRP may result in better proliferative 
effects on SDSCs and chondrocytes compared with those of P-PRP. 
Regarding the negative effects of PRP on chondrogenesis, regardless of the 
presence of leukocytes, several studies (42, 77, 78) showed similar results. 
Liou et al. (77) investigated the effect of PRP on chondrogenic differentiation 
of human MSCs derived from the infrapatellar fat pad and bone marrow and 
found that PRP did not improve chondrogenesis of MSCs of different origins. 
Moreover, chondrogenesis was inhibited with increasing PRP concentrations 
and the duration of exposure; therefore, the researchers concluded that PRP 
was unlikely to enhance the MSC-mediated hyaline cartilage regeneration. 
Furthermore, Lee et al. (42) showed that PRP had negative effects on 
chondrogenic differentiation of SDSCs and PRP alone did not induce SDSC 
differentiation. In addition, O’Donnell et al. (78) showed that the PRP 
obtained from older patients with knee OA downregulated the type II collagen 
and Sox-9 gene expression while upregulating that of TNF-α and MMP-9 in 
chondrocytes. Therefore, the authors concluded that PRP might suppress the 
synthesis of the chondrocyte matrix and promote inflammation.  
However, several studies (39, 40) have reported opposite results. Mishra et al. 
(40) showed that PRP induced 10-fold increases in the Sox-9 and aggrecan 
gene expression in MSCs (origin unreported) compared with that in the 
control and concluded that PRP enhanced chondrogenic differentiation of 
MSCs. Additionally, Jeyakumar et al. (39) reported that PRP increased type 2 
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collagen gene expression in chondrocytes and concluded that PRP enhanced 
redifferentiation of chondrocytes. However, these studies are difficult to 
compare with our study, owing to different experimental conditions, 
especially properties of PRP. As described by Russell et al. (79), the time and 
speed of centrifugation, method of PRP activation, time interval between PRP 
preparation and application, and method of application all play an important 
role in the efficacy of PRP. Indeed, Kreuz et al. (28) showed that the use of 
PRP samples prepared using different methods resulted in different 
proliferation abilities and chondrogenic differentiation potential of BMSCs. 
Therefore, the availability of standardized methods of PRP preparation and 
application is crucial to minimize variability between studies and determine 
the actual effect of PRP on chondrogenesis. 
This study has several limitations. First, we only evaluated the effects of L-
PRP and P-PRP on SDSCs, while those on MSCs from the bone marrow or 
adipose tissue may still be different. Second, there were inconsistencies; 
chondrogenic marker genes were markedly upregulated, whereas, type II 
collagen and proteoglycan were not synthesized well in the presence of P-PRP. 
As protein-coding genes are eventually translated into proteins, it is usually 
accepted that there is a positive correlation between gene and protein 
expression levels. There are three possible explanations for the poor 
correlation between gene and protein expression. First of all, there are many 
complex and diverse posttranscriptional mechanisms involved in mRNA 
translation into a protein, which are not yet fully understood (80). 
Furthermore, protein expression levels at the time of measurement can be 
influenced by the protein turnover rate, which can be greatly affected by cell 
culture conditions (81). Lastly, there is the possibility of measurement errors 
in detection of both gene and protein expression (82). However, considering 
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that cell culture conditions and method of measurement did not vary much 
among the three groups, we assume that our result is mainly the outcome of 
potential negative effects of some growth factors in PRP on protein synthesis 
during posttranscriptional mechanism. Third, we obtained chondrocytes and 
SDSCs from older female patients, who had advanced knee OA. Considering 
that the proliferation and chondrogenic potential of chondrocytes and SDSCs 
are largely affected by the age of the donor and the grade of knee OA (83), 
older OA patients undergoing total knee arthroplasty may not be an ideal 
source of these cells for experiments. However, we used this alternative 
source because obtaining sufficient volumes of the cartilage and synovium 
from a young healthy donor may have raised ethical issues. Fourth, the 
evaluation of chondrogenesis using pellet culture was assessed at only one 
time point, namely 3 weeks after culture. However, several studies (84-86) 
have shown that although the expression of early stage chondrogenic marker 
genes and corresponding protein (Sox-9, aggrecan, type II collagen) synthesis 
did not appear distinctly at 1 week, these genes and proteins were increased at 
2 weeks, and were considerably higher at the end of 3 weeks of differentiation. 
Moreover, Gong et al (84) showed that between 2 to 3 weeks of 
differentiation, late chondrogenic marker gene such as type X collagen, which 
causes cartilage hypertrophy and calcification, increased significantly. 
Therefore, we believe that measuring at 3 weeks after culture best reflects the 
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III-1. Materials and Methods 
 
Preparation of PRP 
Nine milliliters of whole blood was obtained under anesthesia from New 
Zealand white rabbits, and the blood was anticoagulated with 1 mL of a 3.8% 
sodium citrate solution. The tube was centrifuged at 2,000 rpm for 5 min, and 
the upper layer of plasma was separated and subjected to a second round of 
centrifugation at 3,000 rpm for 10 min, followed by the collection of the 
lower 1 mL of plasma as PRP. 
 
Surgical Procedure 
The knee joints were exposed through a medial parapatellar incision, and the 
patella was everted laterally to expose the trochlear groove of the rabbits. A 
full-thickness cartilage defect of 4 mm in diameter and 3 mm in depth was 
made in the trochlear groove using a hand drill. Before transplantation, the 
joints were thoroughly irrigated with a sterile saline solution. Eighteen male 
New Zealand white rabbits were divided into three groups (n = 6 each) as 
follows: control group, in which the defect was left untreated; HA group, in 
which the defect was filled with an HA hydrogel (200 µL/defect); and HA-
PRP group, in which the defect was filled with HA hydrogel and 10% PRP 
(200 µL/defect). To make HA hydrogel, HA solution (10 mg/mL, LG CI) was 
mixed with fibrinogen (120 mg/mL, Greenplast kit; Green Cross) and then 
thrombin (10 mg/mL) containing 40 mM CaCl2 to form a gel. After the soft 
tissue and skin were closed, the rabbits were housed in separate cages and 
allowed to move freely without joint immobilization after surgery. 
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Macroscopic Examination 
The rabbits were sacrificed at postoperative 12 week by intravenous overdose 
of a ketamine solution (15 mg/kg). The distal femurs were dissected, and the 
macroscopic appearance of the defects was evaluated using the International 




After macroscopic examination, the distal femurs were fixed in 10% buffered 
formalin for 5 days, then decalcified using the Decal Rapid decalcifying agent 
(National Diagnostics, Atlanta, GA, USA) for 2 days, dehydrated with a 
graded series of ethanol solutions, embedded in paraffin, and cut into 5-mm-
thick sagittal sections. The sections were stained with hematoxylin and eosin 
(H&E) for morphological evaluation and with safranin-O/fast green for 
proteoglycan content evaluation. The sections were evaluated by three trained 
observers to determine O'Driscoll histological cartilage repair scores (Table 3). 
 
Determination of the GAG Content 
Total glycosaminoglycan (GAG) contents were assessed at 12 weeks after 
surgery using the dimethylmethylene blue (DMB) assay. Samples were 
digested with a papain buffer at 65°C for 18 h. After centrifugation at 6,000 
rpm for 5 min, 50μL aliquots were placed on 96-well plates with 250μL of the 
DMB solution. Absorbance of these extracts was measured at 530 and 590 nm 
using a plate reader, and the values were standardized by the absorbance of 
the chondroitin-6-sulfate standard. The total GAG per gram of wet weight of 
the cartilage was calculated for each sample. 
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Statistical Analysis 
The Kruskal–Wallis test, followed by multiple significance analyses involving 
the Mann–Whitney test, was used to compare scores among the groups. A 
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Table 2. ICRS macroscopic evaluation of cartilage repair. 
 
Categories Score 
Degree of defect repair  
In level with surrounding cartilage 4 
75% repair of defect depth 3 
50% repair of defect depth 2 
25% repair of defect depth 1 
0% repair of defect depth 0 
Integration with border zone  
Complete integration with surrounding cartilage 4 
Demarcating border <1 mm 3 
3/4 of graft integrated, 1/4 with a notable border >1 mm width 2 
1/2 of graft integrated with surrounding cartilage. 1/2 with      a 
notable border >1 mm 
1 
From no contact to 1/4 of graft integrated with surrounding 
cartilage 
0 
Macroscopic appearance  
Intact smooth surface 4 
Fibrillated surface 3 
Small, scattered fissures or cracks 2 
Several, small or few but large fissures 1 
Total degeneration of grafted area 0 
Overall repair assessment  
Grade I: normal 12 
Grade II: nearly normal 11-8 
Grade III: abnormal 7-4 
Grade IV: severely abnormal 3-1 
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Table 3. O’Driscoll histological scores 
 
Characteristics Score 
1. Cell morphology  
Hyaline like articular cartilage 4 
Partial differentiated hyaline cartilage 2 
Fibrous tissue 0 
2. Integrity of surface  
Surface smooth and intact 3 
Surface horizontal fibrillation 2 
Surface shows fissures to 25–100% of the depth of the cartilage 1 
Serious deep interruption of the surface and many deep 
fibrillations 
0 
3. Thickness  
100% of normal host cartilage 2 
50–100% of normal cartilage 1 
0–50% 0 
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5. Chondrocyte clustering 
None at all 2 
<25% of the cells 1 
25–100% of the cells 0 
6. Degenerative changes  
Normal cell quantity, no clustering, normal staining with 
proteoglycan specific stain 
3 
Normal cell quantity, some cluster formation, moderate staining 2 
Clearly less cells, poor staining 1 
View cells, no or very little staining 0 
7. Restoration of the subchondral bone  
Normal and straight 4 
Slight contour changes 2 
Larger interruptions in subchondral bone 1 
Defect 0 
8. Integration  
Both sides of repair tissue integrated with host cartilage 2 
One side integrated 1 
No integration 0 
Total maximal score 23 
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III-2. Results 
 
Results of Macroscopic Examination 
At 12 weeks after operation, a partially healed cartilage was observed within 
the defect, but the margin was clearly distinguished from the surrounding 
intact cartilage in all three groups (Figure 12). There were no differences in 
the macroscopic ICRS scores among the three groups (Figure 13). 
Results of Histological Examination 
At 12 weeks after operation, the HA-PRP group showed better histological 
features with both H&E and safranin-O/fast green staining than did the 
control and HA groups (Figure 14). However, the HA and HA-PRP groups 
showed significantly higher O’Driscoll scores than did the control group (p < 
0.05 for all comparison), whereas the scores were not different between the 
HA and HA-PRP groups (Figure 15). 
 
GAG Content 
The GAG content was significantly higher in the HA and HA-PRP groups 
than in the control group (p < 0.05 for all comparison) but was not different 
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Figure 12. Macroscopic appearance of defects in trochlear groove (4 mm in 
diameter) at 12 weeks after surgery in control group (A), HA group (B), HA-
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Figure 13. ICRS macroscopic scores for control group, HA group, HA-PRP 
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Figure 14. Histologic appearance of defects in trochlear groove (4 mm in 
diameter) with H&E staining (A-C) and Safranin-O staining (D-I) at 12 weeks 
after surgery in control group (A, D, G), HA group (B, E, H), HA-PRP group 
(C, F, I). G, H and I are magnified views of the boxes in D, E, and F. The 
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Figure 15. O’Driscoll histologic scores for control group, HA group, HA-
PRP group at postoperative 12 weeks. HA and HA-PRP group showed 
significantly higher scores compared with that in the control group, but it was 
not different between HA and HA-PRP group. Results are presented as mean 
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Figure 16. GAG content for control group, HA group, HA-PRP group at 
postoperative 12 weeks. The GAG content was significantly higher in the HA  
and HA-PRP group compared to that in the control group, but it was not  
different between the HA and HA-PRP group. Results are presented as mean  
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III-3. Discussion 
The most important findings in this study were that (1) the macroscopic ICRS 
scores were not different among the three groups and (2) the HA and HA-PRP 
groups showed significantly higher histological scores and a significantly 
higher GAG content than the control group, although the values were not 
different between the HA and HA-PRP groups. Therefore, we concluded that 
the addition of PRP did not provide an additional effect on cartilage 
regeneration in vivo compared with that of the scaffold alone. 
The most critical limitation of articular cartilage regeneration techniques has 
been an inability to restore the normal biochemical and mechanical function 
of the native hyaline cartilage, which is essential (43, 44). The bone marrow 
stimulation technique involves the recruitment of endogenous MSCs from the 
bone marrow to a cartilage lesion, and cartilage regeneration is possible 
because mesenchymal progenitor cells have high proliferation potential and a 
high ECM synthesis capacity (87, 88). However, the mesenchymal progenitor 
cells recruited via the bone marrow stimulation technique are too small, and 
there is a possibility of cell leakage because the endogenous fibrin clot formed 
by this technique cannot effectively hold these cells. To overcome the 
shortcomings of the bone marrow stimulation technique, various scaffolds 
have been developed, which provide a suitable environment for MSC 
expansion and chondrogenic differentiation (54, 55). Several studies have 
shown more favorable outcomes when the bone marrow stimulation technique 
was used in combination with scaffolds rather than alone (50, 51, 53). 
PRP contains various growth factors, including PDGF, TGF-β1, VEFG, IGF, 
and FGF, which can promote cartilage formation. PDGF is a strong mitogen, 
and it helps chondrocytes proliferate and induce ECM synthesis (12). 
Furthermore, TGF-β1 plays a role in chondrogenic differentiation of MSCs 
- ５４ - 
and in the regulation of activity of catabolic growth factors such as IL-1β and 
MMP-9 (11). VEGF is the most potent proangiogenic growth factor, whereas 
IGF-1 is one of the main anabolic growth factors in the cartilage, which 
inhibits IL-1β-induced inflammation (13). FGF stimulates the proliferation 
and chondrogenic differentiation of MSCs (10). Therefore, theoretically, 
using PRP-augmented scaffolds in combination with the bone marrow 
stimulation technique seems advantageous and may provide an additional 
benefit by accelerating cartilage regeneration. 
However, in our study, there was no difference in histological scores and the 
GAG content between the HA and HA-PRP groups, indicating that there was 
no additional effect of PRP on cartilage regeneration. There are several 
possible reasons, one of which is the type of the scaffold. In this study, an 
HA-based hydrogel was selected as a scaffold because HA is a major 
component of the articular cartilage, and several studies have shown that HA 
can provide a suitable microenvironment for chondrogenesis (56, 58). 
However, there are various types of scaffolds, and conflicting results have 
been reported depending on which scaffold was used in combination with 
PRP for cartilage regeneration (89-93). Kon et al. (91) found that PRP 
combined with type I collagen scaffolds decreased the cartilage regeneration 
capability in a sheep osteochondral defect model. However, Sun et al. (93) 
showed that the addition of PRP to a polyglycolic acid scaffold additionally 
stimulated cartilage regeneration in a rabbit osteochondral defect model. 
Moreover, not only the type of the scaffold but also the presence of 
chondrocytes or stem cells in the scaffold is an important factor. Sermer et al. 
(94) conducted a systematic review and found that the use of PRP with cell-
induced scaffolds generally showed superior cartilage healing over that of 
PRP with cell-free scaffolds. In cell-induced scaffolds, cells directly 
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differentiate to chondrocytes or produce ECM, without the need for native 
MSCs to migrate into the scaffold, whereas in the case of cell-free scaffolds, 
cartilage regeneration exclusively relies on migrated MSCs. The other factors 
contributing to the conflicting results are characteristics of the PRP used. The 
quality and quantity of growth factors in PRP depend on the method of PRP 
preparation, storage conditions, and method of activation (26, 27, 66, 79). 
Considering that cartilage regeneration is a complex process, which involves 
various molecular pathways, even small differences in growth factors in PRP 
can result in differences in cartilage regeneration. 
This study has several limitations. First, in vivo chondrogenesis was assessed 
at only one time point, 12 weeks after operation, which we considered to be a 
sufficient time for chondrogenesis to proceed and be evaluated. However, in a 
rabbit osteochondral defect model, Shapiro et al. (95) showed that 
degeneration of repaired tissue could occur after postoperative 12 weeks. 
Therefore, a longer evaluation period may be needed to verify long-term 
effects on chondrogenesis. Second, we did not evaluate the effect of PRP 
alone on in vivo chondrogenesis, as this study mainly aimed to evaluate an 
additional effect of PRP in combination with an HA hydrogel. Moreover, 
when PRP is used alone, the growth factors, which are only released in an 
early period, may then be washed away by bodily fluids under in vivo 
conditions (23, 24). 
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Conclusion 
Growth factor concentrations in PRP significantly differed depending on the 
storage temperature, duration of storage, and activation. Regardless of the 
leukocyte concentration, PRP showed a negative effect on chondrogenesis of 
SDSCs and chondrocytes. In addition, combined use of an HA hydrogel and 
PRP did not show additional chondrogenic effects in vivo compared with 
those of the HA hydrogel alone. Considering the results of our study, a further 
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국문 초록 
 
목 적: 본 연구에서는 혈소판 풍부 혈장을 이용한 연골재생에 대해 
알아보고자 한다. 이를 위해 먼저 보관조건에 따른 혈소판 풍부 혈장 내 
성장인자 농도를 조사하고, 혈소판 풍부 혈장 내 백혈구 농도 차이가 
인체활막세포와 연골세포에 미치는 영향을 알아본 후, 마지막으로 혈소판 
풍부 혈장과 지지체의 복합체 형성이 연골재생에 미치는 영향을 
알아보았다. 
 
대상 및 방법: 보관조건에 따른 혈소판 풍부 혈장 내 성장인자 농도를 
조사하기 위해, 혈소판 풍부 혈장을 24도, 4도, -70도에서 7일 동안 
보관한 후 활성화 전후로 PDGF‐AA, TGF‐β, VEGF, IGF‐1, FGF‐B 
농도를 ELISA를 이용하여 측정하였다. 또한 혈소판 풍부 혈장 내 백혈구 
농도 차이가 인체활막세포와 연골세포에 미치는 영향을 알아보기 위해, 
백혈구 풍부 (Leukocyte-rich)와 순수 (Leukocyte-poor) 혈소판 풍부 
혈장을 제조하고 이들을 각각 인체활막세포, 연골세포와 같이 3주간 pellet 
배양하였다. 이후 세포 증식을 MTT assay로 평가하고, 연골형성능은 
RT-PCR로 연골형성에 관련된 유전자 (Type II collagen, Type X 
collagen, SOX-9, aggrecan) 발현을 측정한 후 조직학/면역학적 염색을 
시행하였다. 마지막으로 혈소판 풍부 혈장과 지지체의 복합체 형성이 
연골재생에 미치는 영향을 조사하기 위해, 토끼 대퇴 활차에 골연골 결손을 
만들고 대조군, 지지체군, 복합체군 (혈소판 풍부 혈장+지지체)으로 나눈 
후 12주에 ICRS macroscopic score와 Modified O’Driscoll score를 
얻고 DMB assay를 통해 GAG 합성을 평가하였다.  
- ７０ - 
결 과: 보관조건에 따른 혈소판 풍부 혈장 내 성장인자 농도의 경우, 
활성화 전 PDGF‐AA 농도는 24도에서 7일째 가장 높았고, TGF‐β는 
모든 온도에서 7일 동안 잘 검출되지 않았으며, VEGF와 IGF‐1 농도는 
모든 온도에서 7일 동안 일정하게 유지되고, FGF‐B 농도는 -4도에서 
7일째 가장 높았다. 활성화 후 PDGF‐AA, VEGF, IGF‐1 농도가 모든 
온도에서 7일 동안 일정하게 유지된 것에 반해, TGF‐β 농도는 모든 
온도에서 7일에 가장 높았고, FGF‐B 농도는 24도에서 1일 후 급격히 
감소하는 양상을 보였다. 혈소판 풍부 혈장 내 백혈구 농도 차이가 
인체활막세포와 연골세포에 미치는 영향의 경우, 백혈구 풍부 혈소판 풍부 
혈장에서 인체활막세포와 연골세포 모두 보다 큰 증식능력을 보였으나, 
RT-PCR의 경우 두 세포 모두 백혈구 순수 혈소판 풍부 혈장에서 보다 
많은 유전자 발현이 관찰되었다. 하지만 인체활막세포와 연골세포의 
조직학/면역학적 염색상, 백혈구 농도에 관계없이 두 혈소판 풍부 혈장 
모두에서 연골 분화가 억제되는 양상이 관찰되었다. 혈소판 풍부 혈장과 
지지체의 복합체 형성이 연골재생에 미치는 영향의 경우, 세군 모두에서 
ICRS macroscopic score에 차이가 없었다. Modified O’Driscoll score와 
GAG 농도의 경우, 지지체군과 복합체군 모두 대조군보다 높았으나, 두 군 
간에는 차이가 관찰되지 않았다. 
 
결 론: 혈소판 풍부 혈장에서 방출되는 성장인자들의 농도는 보관온도, 
보관기간, 활성화 여부에 따라 큰 차이가 있었다. 또한 혈소판 풍부 혈장 내 
백혈구 농도에 관계없이 혈소판 풍부 혈장은 인체활막세포와 연골세포의 
연골형성에 부정적인 영향을 보였으며, 혈소판 풍부 혈장과 지지체의 
복합체 사용은 지지체 단독 사용에 비해 향상된 연골형성으로 이어지지 
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못했다. 이번 연구결과들을 기반으로 연골재생을 위한 최적의 혈소판 풍부 
혈장 사용에 대한 추가연구가 필요 할 것으로 생각된다. 
 
색인 단어: 혈소판 풍부 혈장, 보관, 백혈구, 활막줄기세포, 
연골세포, 지지체 
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